Novo Nordisk commits $4.1 billion to North Carolina plant making Ozempic and Wegovy
Novo's biggest U.S. production bet is aimed at easing supply limits on its GLP-1 drugs, though the added capacity does not arrive until late in the decade.
Novo Nordisk said on June 24, 2024 that it will spend $4.1 billion — about 27 billion Danish kroner — on a second fill-and-finish factory in Clayton, North Carolina, an investment the Danish drugmaker described as one of the largest manufacturing commitments in its history [1].
The building is planned at 1.4 million square feet of aseptic manufacturing and finished-production space, which Novo says would double the combined floor area of its three existing sites in the state [1]. The company expects 1,000 permanent hires on top of the nearly 2,500 people it already employs in the region, and roughly 2,000 outside contractors at the peak of construction [1].
FiercePharma reported that the plant will make Ozempic, the semaglutide injection for type 2 diabetes, and Wegovy, the semaglutide injection for obesity [2]. Novo's own announcement did not name products, saying only that the site will expand its ability to produce "current and future injectable treatments for people with obesity and other serious chronic diseases" [1].
Site work has begun on 56 acres, and Novo says construction will finish in phases between 2027 and 2029 [1]. Across its global network, the company plans to spend about $6.8 billion on production in 2024, compared with $3.9 billion in 2023, a figure that does not include acquisitions [1].
"It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we're building Novo Nordisk's ability to serve millions more people living with serious chronic diseases in the future," president and CEO Lars Fruergaard Jørgensen said [1].
Henrik Wulff, executive vice president for product supply, quality and IT, said Clayton was Novo's first U.S. manufacturing site and remains a cornerstone of the company's growth [1]. Butch Lawter, chair of the Johnston County Board of Commissioners, announced county grants for the project and said the 2016 facility announcement across the road had been the largest life-sciences investment on state record at the time, and that the new one breaks it [1].
FiercePharma reported that the second Clayton plant, which came online in 2021, cost $2 billion and was the largest life-science project in North Carolina at that point, and that Novo's Durham site about 40 miles away makes Rybelsus, the oral form of semaglutide [2]. The report also noted that Eli Lilly had unveiled a $5.3 billion manufacturing investment a month earlier, as the two companies compete for production capacity, and that Novo's parent, Novo Holdings, is pursuing a $16.5 billion buyout of the contract manufacturer Catalent that would give Novo Nordisk three fill-finish sites for $11 billion [2].
Why it matters for patients
Both companies are adding capacity because demand for GLP-1 medicines has run ahead of what their factories can supply [2]. The timing is the detail that matters most: no medicine from the Clayton expansion reaches patients until late in the decade, so near-term availability rests on the plants Novo already operates [1][2].
What the new site will mean for U.S. supply of Ozempic or Wegovy has not been disclosed. Novo has not said how much capacity the facility will add, how its output will be divided among medicines, or whether any specific share is intended for the American market [1][2]. The product names come from FiercePharma's reporting, not from the company's release [1][2]. Whether the 1,000 new jobs are tied to semaglutide production specifically also has not been reported [1].
Novo said the facility is designed with roof-top solar panels and water-saving systems, and that it is aiming for LEED Gold certification, a green-building standard [1].
What happens next
- 2024: early site work continues, and Novo's planned production spending for the year is about $6.8 billion, excluding acquisitions [1].
- 2027 to 2029: construction is completed in stages [1].
- Staffing: 1,000 permanent positions, plus up to 2,000 contractors at the project's busiest point [1].
- Separately pending: Novo Holdings' proposed $16.5 billion Catalent acquisition [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.